Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 15, 2020 - Issue
Submit an article Journal homepage
89
Views
1
CrossRef citations to date
0
Altmetric
Original Research

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies

James F Donohue1 Department of Pulmonary Diseases and Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4439-6866
ORCID Icon,
Ayca Ozol-Godfrey2 Sunovion Pharmaceuticals Inc., Marlborough, MA, USA
,
Thomas Goodin2 Sunovion Pharmaceuticals Inc., Marlborough, MA, USA
&
Shahin Sanjar2 Sunovion Pharmaceuticals Inc., Marlborough, MA, USAORCID Iconhttps://orcid.org/0000-0003-1462-436X
ORCID Icon
Pages 745-754 | Published online: 14 Apr 2020

References

  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD, 2020. Available from: http://goldcopd.org/. Accessed 212, 2020.
  • JenkinsCR, PostmaDS, AnzuetoAR, et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm Med. 2015;15:97. doi:10.1186/s12890-015-0077-026293575
  • PunekarYS, SharmaS, PahwaA, TakyarJ, NayaI, JonesPW. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. Respir Res. 2017;18(1):86. doi:10.1186/s12931-017-0566-128482883
  • ChapmanKR, BatemanED, ChenH, HuH, FogelR, BanerjiD. QVA149 improves lung function, dyspnea, and health status independent of previously prescribed medications and COPD severity: a subgroup analysis from the SHINE and ILLUMINATE studies. Chronic Obstr Pulm Dis. 2015;2(1):48–60. doi:10.15326/jcopdf.2.1.2014.014028848830
  • PhamS, FergusonGT, KerwinE, GoodinT, WheelerA, BauerA. In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution. J Aerosol Med Pulm Drug Deliv. 2018;31(3):162–169. doi:10.1089/jamp.2017.138429125918
  • Lonhala Magnair (glycopyrrolate) inhalation solution [highlights of prescribing information]. Sunovion Pharmaceuticals, Inc; 2019
  • KerwinE, DonohueJF, GoodinT, TosielloR, WheelerA, FergusonGT. Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respir Med. 2017;132:238–250. doi:10.1016/j.rmed.2017.07.01128838685
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD, 2014. Available from: http://goldcopd.org/. Accessed 520, 2019.
  • JonesPW. St. George’s respiratory questionnaire: MCID. COPD. 2005;2(1):75–79. doi:10.1081/COPD-20005051317136966
  • LeidyNK, MurrayLT, MonzBU, et al. Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res. 2014;15:124. doi:10.1186/s12931-014-0124-z25287629
  • KerwinE, FergusonGT. An overview of glycopyrrolate/eFlow® CS in COPD. Expert Rev Respir Med. 2018;12(6):447–459. doi:10.1080/17476348.2018.147685329774778

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.